THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Jeremy Wyatt, CTO & Senior VPActiGraph’s technology ecosystem can be tailored to the specific needs of CROs and sponsors to provide integrated solutions for even the most complex studies. CentrePoint, ActiGraph’s cloud-based logistics platform, simplifies technology deployment, while optimizing the value of mHealth in clinical trials by providing access to near real-time patient data using an innovative cellular data hub. The ActiGraph team is working to make CentrePoint a single point of data collection for both their activity monitors and other sensors, making the data even more meaningful.
A key differentiator for the ActiGraph product suite is the ability to capture real-time, real-world data that helps clinical and research teams to analyze patient behaviors and make quick and well-informed decisions. ActiGraph solutions not only provide an efficient and cost-effective means of collecting data, but they also optimize the capabilities of the involved research or clinical teams.
Our mission is to provide the solutions that allow our customers to improve clinical trial efficiency and patient outcomes
The importance of collecting useful and validated data is something the data collection industry has battled with for decades. A surplus of data is collected in clinical trials, and clinical teams often fall into a labyrinth of navigating through useless information to find the meaningful data. ActiGraph’s system aims to bridge this gap in data collection by strictly targeting relevant endpoints for each study and tracking compliance and effects in near real time.
ActiGraph has worked with the world’s leading academic and research institutions, such as Harvard, Johns Hopkins, and Vanderbilt, to advance the understanding of how sleep and activity can be quantified in the face of a wide range of variables such as populations, disease states and ages. “For nearly 13 years, we’ve helped teams like the National Institute of Health (NHANES study) and the German Health Study (NAKO study) move the needle on both population health and disease by understanding the impacts of physical activity and sleep,” adds Wyatt.
The future for ActiGraph’s product suite is paved with multiple iterations and innovation. “We believe that our cellular powered CentrePoint Data Hub can circumvent in-home patient technology issues by eliminating the need to install apps on smartphones, train patients on those apps, and plan for the various operating systems that are out there.” The Data Hub, aimed at simplifying the entire process of integrating data, gives ActiGraph the opportunity to bypass site-level IT restrictions that often prevent the installation of wearable-specific software on site computers. Per Wyatt, “We believe that eventually our data will integrate with other sources like EMR, genomic, and ePRO data to really improve drug development and patient care.”
Company
ActiGraph
Management
Jeremy Wyatt, CTO & Senior VP
Description
ActiGraph provides clinical grade physical activity and sleep monitoring hardware and software solutions for the global scientific community
ActiGraph invited uMotif to join its Accelerant™ Partner Program because of uMotif’s unique focus on the patient experience. uMotif’s patient-first approach is delivering greater than 90% eCOA/ePRO compliance in both clinical trials and real-world studies – providing more and better-quality subjective data to sites, sponsors and CROs. Built by global experts in consumer design, clinical research technology and patient-first healthcare, the uMotif platform delivers new innovation in eCOA/ePRO.
By working together, the combined uMotif and ActiGraph solution will provide a more seamless, simple and engaging patient experience for any research study. Sponsors are increasingly focused on making trials more patient-centric, particularly those adopting hybrid and decentralized designs and capturing a range of data from patients, sensors and devices. New study designs can add complexity and burden for patients, sites and CROs, which is compounded by the need to work with multiple systems. uMotif’s and ActiGraph’s unique expertise and design-led approach provides a highly engaging and patient-friendly solution to capture both subjective ePRO and objective device data through a single experience.
Putting patients first is in uMotif’s DNA. The company’s experience over the past 10 years has proven that a patient-centered approach is vital to delivering effective studies at pace and scale, with unrivaled volumes of quality data. uMotif studies have engaged thousands of participants who have captured millions of data points for published research. The new partnership with ActiGraph allows sponsors to capture clinical-grade actigraphy data alongside validated, patient-friendly eCOA/ePRO instruments.
uMotif CEO Steve Rosenberg (LinkedIn) said, “We’re delighted to partner with ActiGraph. Our eCOA/ePRO solutions combined with ActiGraph’s wearables and science-based algorithms and services are a big step forward in putting patients’ comfort and convenience at the center of research, so we can collect massive amounts of quality data while making their lives a bit easier.”
ActiGraph CEO Jeremy Wyatt (LinkedIn) said, “Working with partners like uMotif makes the ActiGraph experience better for patients and clinicians. We are excited to collaborate on a combined solution that will help bring new treatments to market faster than ever.”